Tetra Radar · FDA Approvals · Decision date
REZZAYO: FDA decision date
CorMedix Inc. (CRMD) · First quarter of 2027
The sNDA was submitted by Mundipharma, the Company’s global development partner, and the FDA has granted priority review with a Prescription Drug User Fee Act (“PDUFA”) target action date in the first quarter of 2027.
Source: 10-Q of 12 November 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.